Analysis of TYK2 P1104A variant in a cohort of colombian patients with pulmonary tuberculosis by Guzmán Zuluaga, Laura Cristina
Guzmán LC, Arias AA, Barrera LF. 
 
 1 
ANALYSIS OF TYK2 P1104A VARIANT IN A COHORT OF COLOMBIAN 
PATIENTS WITH PULMONARY TUBERCULOSIS. 
 
Student:  
Laura Cristina Guzmán Zuluaga  
Biology Student, Universidad Eafit  
 
Tutor:  
Andres Augusto Arias Sierra 
Primary Immunodeficiencies Group (IDP), Universidad de Antioquia 
Co-tutor:  
Luis Fernando Barrera 




Tuberculosis continues to be one of the main causes of death worldwide with around 10 
million people infected annually, which is a direct problem for public health. Data that has 
accumulated over decades suggests that variability in human susceptibility to tuberculosis 
disease has a strong genetic component. Both primary and acquired immunodeficiencies 
(PID) are strongly related to broad infectious phenotypes that include the full range of 
diseases caused by the infectious agent Mycobacterium tuberculosis; Recently it was found 
that a PID found in up to 1/600 individuals of European descent, in fact a variant was found 
that affects the catalytic activity of TYK2 therefore selectively alters the immunity to IFN-g 
mediated by IL-23 while the responses to IL-10, IL-12, and IFN-a / b are intact. These PIDs 
are only expressed symptomatically after exposure to Mycobacterium tuberculosis. 
However, we hypothesize that homozygous for the P1104A variant or compound 
heterozygosity in this same TYK2 gene can confer a selective response, thus predisposing to 
TB. This study intends to 1. Identify the variant P1104A of the TYK2 gene in Colombian 
patients with pulmonary tuberculosis, 2. Identify other rare or common variants in the TYK2 
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gene in patients with pulmonary tuberculosis, 3. Correlating data from the Colombian 
population with what has been found in other populations 
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Tuberculosis (TB) is one of the world's 
major public health problems, infecting 
around a third of its population. According 
to the annual report on global tuberculosis 
control of the World Health Organization, 
in 2018, it is estimated that the active 
prevalence of tuberculosis is around 10 
million people, and that of infection (latent 
TB) is approximately 1.8 billion people in 
a number that has remained relatively 
stable in recent years. All these figures 
place TB within the top 10 causes of 
mortality in the world infectious diseases, 
occupying the top positions worldwide. In 
the same year, there were 1.2 million 
deaths from tuberculosis among HIV-
negative people, and another 251,000 
deaths among HIV-positive people. 
Geographically, the majority of 
tuberculosis cases in 2018 were in the 
WHO Regions of South-East Asia (44%), 
Africa (24%), and the Western Pacific 
(18%), with lower percentages in the 
Eastern Mediterranean (8%), the Americas 
(3%) and Europe (3%). (1).  
 
Tuberculosis is a disease in which social, 
economic, environmental (overcrowding, 
large families, poor asepsis, darkness, and 
humidity) (2), and mainly genetic factors 
(2–4) profoundly influence host 
susceptibility. In Colombia, as in other 
regions of the world, it is one of the leading 
public health problems. In the last 43 
years, nearly 500,000 cases of tuberculosis 
have been reported. Although the 
incidence rate has decreased from 58.62 
cases per 100,000 inhabitants in 1970 to 33 
cases per 100,000 inhabitants in 2013, the 
number of cases detected annually has 
remained stable (1). 
 
In 2018, more than 16 thousand cases of 
active TB with an incidence of 33 per 
100,000 inhabitants (1), and around 65% 
of the cases were concentrated in the most 
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productive segment of the population (20-
59 years) (5–7). The department of 
Antioquia reports the highest number of 
cases, and Medellín, the capital of this 
department, is the city of Colombia that 
reports the highest number of cases with an 
incidence of 53 per 100,000 inhabitants, 
but some localities have a high incidence 
(100-200 per 100,000 population). 
However, at the population level, there are 
no clear reports on the number of 
infections that result from non-tuberculous 
mycobacteria (NTM), therefore it is 
reasonable that the prevalence of 
mycobacterial disease could be higher (8). 
 
Mycobacterium tuberculosis (Mtb) is the 
specific agent of human TB. The most 
frequent form of the disease is pulmonary 
TB (86% approximately). TB (9, 10). The 
majority (90-95%) of primary infections 
do not produce clinical symptoms and 
eventually enter a latent phase in a 
condition presently known as latent TB 
disease (11–14). A variable percentage of 
latent infections (5-10%) is reactivated 
with the disease's signs and symptoms 
(active TB). The infection is not usually 
transmitted during the primary stage and 
does not spread in the latent phase. When 
someone develops active tuberculosis, 
symptoms (cough, fever, night sweats, 
weight loss, hemoptysis, among other 
symptoms) may be mild for many months 
(14). This can delay the affected person to 
seek medical attention, with the 
consequent risk of the bacteria being 
transmitted to other subjects. A person 
with active TB can infect between 10 and 
15 people by direct contact over a year. 
Without adequate treatment, over 45% of 
HIV-negative people with TB and nearly 
all people with TB/HIV co-infection will 
die (1). 
 
In recent years, a large number of clinical 
and epidemiological studies have 
suggested that Mtb infection and TB per se 
have a strong genetic basis (15, 16). 
Candidate gene studies have shown 
evidence of an association between host 
genetic polymorphisms and TB 
susceptibility in different human 
populations. Genes such as chemokine (C-
C motif) ligand-2 (CCL-2)/monocyte 
chemoattractant protein 1 (MCP-1), 
natural resistance-associated macrophage 
protein 1 (NRAMP-1)/solute carrier 
protein 11A1 (SLC11A1), IRGMI, 
interleukin (IL) 8, several Toll-like 
receptors (TLR), and nucleotide-binding 
oligomerization domain-containing 
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protein 2 (NOD 2) genes, among others 
(17–22). Accordingly, TB is an infectious 
disease caused by M. tuberculosis, 
prepared and determined by genetic 
polymorphism. These genetic factors play 
a fundamental role in pathogenesis and 
directly influence and modulate the 
immune response, which is why not 
everyone develops the disease. 
 
Both primary (PID) and acquired 
immunodeficiencies are strongly related to 
broad infectious phenotypes that include 
the full range of diseases caused by the 
infectious agent Mycobacterium 
tuberculosis (Chronic Granulomatous 
Disease (CGD), defects in NF-kB-
mediated signaling, hereditary defects in 
the nicotinamide adenine dinucleotide 
phosphatase (NADPH) oxidase complex, 
among others), which supports the 
hypothesis that some defects in the 
immune system could be associated with 
the pathogenesis of TB (23). In this 
context, Mendelian Susceptibility to 
Mycobacterial Diseases (MSMD) is a rare 
group of PIDs characterized by the 
presence of selective susceptibility to 
clinical disease caused by BCG vaccines 
and environmental mycobacteria (NTM), 
and may even present tuberculosis caused 
by Mycobacterium tuberculosis (24–28), 
in otherwise healthy patients, and who are 
normally resistant to other organisms. So 
far, 15 genes have been associated with the 
MSMD condition with allelic 
heterogeneity explaining 30 genetic 
disorders, mainly associated with the 
interferon gamma (IFN-γ) immunity 
(29).From those genes, autosomal 
recessive (AR) interleukin-12 receptor 
deficiencies (IL12RB1) and tyrosine 
kinase 2 (TYK2 variant P1104A) are the 
only two inborn errors of immunity 
reported to date underlying primary 
tuberculosis in patients (30, 31). Together, 
these studies demonstrate the first 
common monogenic cause of TB in 
humans. 
 
TYK2 is a Janus kinase involved in four 
cytokine signaling pathways (those 
mediated by IL-12, IL-23, IFN-α, and IL-
10). The consequences of complete 
deficiency in the TYK2 gene differ 
according to the pathway that is affected, 
when responses are affected to IL-12 and 
IL-23 the result is mycobacterial 
susceptibility (MSMD and TB) (32, 33), 
impaired responses to IFN-α leading to 
viral infections (34), impaired responses to 
IL-10 are clinically silent (35, 36). Despite 
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this, only half of the patients with this 
complete deficiency have developed BCG 
disease even when they have been 
vaccinated with BCG, which shows 
incomplete penetrance for MSMD. This 
can explain or provide proof that 
tuberculosis may be monogenetic but does 
not explain the public health problem.  
 
Based on the Boisson-Dupuis (3) study, it 
was estimated that the penetrance of TB is 
high (at least 50%) in endemic disease 
areas, while that of MSMD is much lower, 
no more than 0.5%, which agrees that M. 
tuberculosis is much more virulent than 
BCG and EM.  
 
The minor allele frequency (MAF) for 
P1104A is 4.2% in the European 
population (from gnomAD) The MAF for 
P1104A is approximately 1 to 2% in other 
parts of the world except in East Asia and 
Sub-Saharan Africa, where it is much 
rarer, if not completely absent. Based on 
ancient DNA studies, it is estimated that 
the frequency of P1104A has decreased 
notably in European populations, which is 
consistent with the purging of TB cases 
throughout history. It is also estimated that 
the homozygosity of this variant may 
underlie a considerable proportion of TB 
cases, perhaps representing ~ 1% of TB 
cases in Europeans and ~ 0.33% of cases 
in most other regions of the world. This 
considerable proportion is based on figures 
that at least in Europe tuberculosis may 
have killed around one billion people (37) 
suggesting that around ten million people 
may have died due to homozygosity of 
TYK2 (P1104A).  
 
In Colombia specifically, it should be 
clarified that the P1104A variant, contrary 
to the previously expressed frequency, is a 
common issue in the study populations, 
but to date, there have not been enough 
studies to decipher the association between 
the P1104A variant in TYK2 and the TB in 
the Colombia, a TB endemic country. In a 
preliminary study carried out by doctoral 
student Carlos Andres Franco with a 
cohort of 722 patients diagnosed with 
pulmonary tuberculosis, no homozygous 
individuals were found, but some were 
heterozygous for the variant. This result 





In heterozygous patients for the TYK2 
P1104A variant, there may be a second 
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Determine the presence of variants in the 
TYK2 gene exons as possible triggers 
associated with active pulmonary TB in 




I. Identify the TYK2 P1104A variant 
in a cohort of Colombian patients 
with pulmonary TB. 
II. Sequence the exons of the TYK2 
gene by the Sanger method. 
III. Identify heterozygous compound 
genotypes in Colombian patients 
with pulmonary TB. 
IV. Correlating data from the 
Colombian population with what 




MATERIALS AND METHODS 
 
Ethics statement 
This study was conducted following the 
Helsinki Declaration, with written 
informed consent obtained from the 
patients, their parents (for minors), and 
other family members. Approval for this 
study was obtained from the Regional 
Ethics Committee of the Universidad de 
Antioquia, Medellin, Colombia. 
 
Studied population  
The genomic DNA (gDNA) samples 
(n=722) used in this study were obtained 
from the Cellular Immunology and 
Immunogenetics Group (GICIG), Faculty 
of Medicine, University of Antioquia. 
These samples were collected from grants 
11150416335, 34261817270, and 
111540820482 (Colciencias, Bogotá, 
Colombia,), in which a cohort of active 
pulmonary TB patients (n=433) was 
followed-up between March 2005 and 
December 2009. More of 90% of the 
recruited TB patients were HIV negative 
and positive for M. tuberculosis infection, 
as assessed by sputum microscopy and 
culture. Under the same criteria, a parallel 
cohort was established in the cities of Cali 
(Departamento del Valle, Colombia; 
n=106), and Popayan (Departamento del 
Cauca; n=26) with active pulmonary TB 
(median age = 33 years, range 18-95), 
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between the years 2005-2006. Eighty 
percent were classified as positive for 
baciloscopy (38, 39) (Figure 1).  
 
Figure 1: Geographical description of the study 
patients 
 
gDNA extraction, qPCR and Sanger 
sequencing 
Genomic DNA was extracted from whole 
blood using the Puregene DNA 
Purification Kit (Gentra Systems, 
Minneapolis, MN). A qPCR method was 
used to identify the TYK2 SNPs 
rs34536443 (C/G) (P1104A) allele 
frequency. For this, a TaqMan® SNP 
Genotyping Assay (Applied Biosystems) 
was used for discrimination of alleles 
encoding TYK2 Pro-1104 and Ala-1104). 
The TaqMan genotyping assay was 
validated using controls of each genotype 
and the results were compare to the 
reference human genome GRCh37. 
Conventional Polymerase chain reaction 
(PCR) was used in order to confirm the 
P1104A presence and to sequence the 
TYK2 exons from 3 to 23 using gDNA as 
template. The oligonucleotides and cycles 
used in each of the PCRs are described in 
supplementary Tables 1, and 3, and 
supplementary Figure 1. The commercial 
Taq polymerase (Thermo Fisher 
Scientific, USA) was used in a reaction 
with a final volume of 40 µL containing 
150 ng of gDNA and 0.2 µM of each of the 
oligonucleotides (supplementary Table 2). 
All the amplicons were analyzed using 2% 
agarose gels.  
 
All the PCR products were sequenced 
using the BigDye Terminator Cycle 
Sequencing Kit (Applied Biosystems) 
using the sense and antisense 
oligonucleotides used for each of the PCR 
reactions. Sequencing products were 
purified using Sephadex G-50 Superfine 
Resin (GE Healthcare). Sequences were 
determined by using ABI 3730 DNA 
Analyzer (Applied Biosystems). 
Sequencing spectrum data were analyzed 
using the SnapGene software. The 
chromatograms obtained were analyzed 
with the SnapGene program using as 
reference the sequence of TYK2 reported 
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in the National Center for Biotechnology 
Information (NCBI) database 
(NG_0078721). The position of the 
variants was determined using the Alamut 
Visual ™ program (Interactive 
Biosoftware, France), version 2.7.2, using 
the GRCh37 reference genome, while the 
analysis of the pathogenesis of the 
mutations found was done with the 
gnomAD, SIFT and PolyPhen programs. 
The nomenclature used to name the 
variants and mutations was based on the 
nomenclature guidelines of the Human 
Genome Variation Society (HGVS). 
 
RESULTS  
Identifying the TYK2 P1104A variant in 
Colombian patients 
In the present study, the TYK2  
p.Pro1104Ala (P1104A) variant 
(rs34536443) was genotyped by qPCR in 
722 Colombian patients with TB. After the 
analysis was carried out, 19 individuals 
with the TYK2 P1104A variant were found 
in a heterozygous condition (15 from 
Medellin, and 4 from Cali) and no 
individual carrying the variant was found 




studied with TB 
Number of homozygous 
individuals for the 
P1104A variant 
Number of individuals 
heterozygous for the 
P1104A variant 
MAF (Minor allele 
frequency) % 
722 0 19 1,3 
Table 2: Study population, individuals homozygous and heterozygous for TYK2 P1104A, and 
MAF. 
 
No homozygous for the P1104A variant of 
the TYK2 gene were found in the 722 TB 
patients. However, 19 heterozygous 
individuals were found, suggesting the 
possibility that other genetic variants 
within the same gene may create a 
predisposition to the development of 
active TB in Colombian patients. The 
allelic frequency (MAF) of the TYK2 
P1104A variant was determined, resulting 
in 1.3% (19/1444) in the studied 
population. The MAF of P1104A. The 
presence of P1104A was confirmed by 
Sanger sequencing as shown as an 
example for patient 16 (P16) (Figure 2). 




Figure 2. Analysis of the TYK2 gene by chromatogram of the sequences corresponding to the healthy 
control and to the patients P16, and P18. A. Chromatograms of exon 23 corresponding to control and 
patient P16. The heterozygous change P1104A is indicated in red by the affected nucleotide (it was 
the same image and result for the 19 heterozygous patients). B. Chromatograms of exon 3 of the 
control, patient P16 and P18. The heterozygous change p.Ala53Thr in both patients are indicated in 
red. The nucleotide position is based on the gDNA sequence reported in the National Center for 
Biotechnology Information (NCBI)
Searching for TYK2 gene variants in a 
Colombian population of TB patients 
 
Therefore, all the coding exons were 
amplified in search of a possible 
heterozygous variant that can explain a 
possible compound heterozygous 
condition with P1104A. The 23 coding 
exons were amplified by conventional 
PCR and confirmed by agarose 
electrophoresis as shown as an example 
for exon 8-9, and 23 (Figure 3) .Some of 
the exons were amplified together since 
they were very small; in total, 304 
amplicons were obtained for analysis by 
the Sanger sequencing. In this search, we 
found that two patients (P16 and P18) as 
the variant g.10488926C>T in TYK2 exon 
3 in an heterozygous condition, resulting 
in a p.Ala53Thr (A53T) previously 
reported in gnomaAD (dbSNP, 
rs55762744)  (Figure 2)
C  T  G  A C  A G  C   T  G A G  G  A  A
Leu51 Thr52 Ala53 Glu54 Glu55
C  T  G  A C  A G/A C TG  A G  G  A  A
Leu51 Thr52 Ala53 Glu54 Glu55
Thr53
C  T  G  A C  AG/AC T  G  A G  G  A  A








C A G  A G C C C C  C  C C A C G
Gln1102 Ser1103 Pro1104 Pro1105 Thr1106
C A G  A G C C/GC C  C  C CA C G






Exon 3 Exon 23 
A B





Figure 3. Agarose Gel Electrophoresis for PCR Products A. Electrophoresis of PCR products from 
exon 8-9 of the TYK2 gene. This exon was amplified by PCR from genomic DNA in the 19 patients 
studied and in the healthy individual that served as a positive control (+). Subsequently, a 2% agarose 
gel electrophoresis was performed using each of the PCR products and the presence of a band 
equivalent to 572 bp was determined by means of GelRed. For the negative PCR control (-), all PCR 
reagents except gDNA were used. B. Electrophoresis of PCR products of exon 23 of the TYK2 gene 
with a band equivalent to 236 bp; (The same protocol was used for all exons). 
 
DISCUSSION  
Two recently published studies (3, 4) delve 
into this genetic question of TB disease 
and reveal, firstly, that the immune 
response to mycobacteria is driven by the 
interleukins IL-12 and IL-23 and, 
secondly, that those people with two 
copies of a variant of the TYK2 gene has a 
high predisposition to develop 
tuberculosis. 
In the first of the studies, the researchers 
analyze the role of the interleukins IL-12 
and IL-23 in the immune response against 
M. tuberculosis. Lack of receptors for 
either of these two immune systems 
signaling molecules leads to high 
susceptibility to mycobacterial infection. 
These experiments of nature show that 
human IL-12 and IL-23 are both required 
for optimal IFN-γ–dependent immunity to 
mycobacteria (4). The second study works 
precisely on this question. The team of 
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variant in the TYK2 gene whose presence 
in homozygosis (in both copies of the 
gene) increases the risk of TB. This 
genetic variant interferes with the 
induction of IFN-γ mediated by IL-23. 
Researchers have found that the frequency 
of the variant has decreased in European 
populations over the past 4,000 years, 
suggesting that natural selection is acting 
to eliminate the alleles responsible for 
increased susceptibility to tuberculosis (3). 
A very interesting aspect this is the 
estimate that about one in every 600 
people of European descent carries both 
copies of the TYK2 gene for TB 
susceptibility (the frequency varies 
between 1 / 1,000 and 1 / 10,000 in other 
populations). This result may be especially 
relevant for some people. The frequency of 
TB and the risk of exposure to the 
infection is low in countries that show a 
higher frequency of carriers of variants of 
susceptibility to the disease. However, if 
these people travel to high-risk regions 
with high exposure, they would have a 
much higher chance of becoming infected 
(3). Therefore, this is the greatest 
relevance of the study. 
Specifically, in this study, no patients were 
found homozygous for the P1104A 
variant. However, 19 individuals were 
heterozygous (15 from Medellin, and 4 
from Cali). Assuming that these patients 
may have another variant in a different 
exon, it was then decided to sequence each 
of the coding exons. In this search, we 
found that two of the patients had the 
p.Ala53Thr variant revealing a possible 
compound heterozygous condition with 
P1104A in these patients.  The p.Ala53Thr 
(rs55762744) is reported in genomeAD as 
a variant encoding a missense mutation in 
exon 3 of the TYK2 and in silico analysis 
by SIFT and PolyPhen predicted this 
variant to be deleterious and probably 
damaging, respectively. It has an allelic 
frequency of 0.7% in total populations and 
0.3% in Latino populations, and has been 
previously associated with susceptibility 
to multiple sclerosis (40). Unfortunately, 
in our case the sequencing method used 
does not allow us to identify the particular 
allele carrying the variant. In this sense, 
the compound heterozygosity is 
hypothetical and further studies are 
necessary.  Furthermore, it will be 
necessary to experimentally determine the 
phenotypic effect of this variant to define 
a potential effect on TB susceptibility, and 
the induction of IFN-γ mediated by IL-23 
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in tests  similar to those performed by 
Boisson-Dupuis S in 2018 (3). 
Comparing TYK2 P1104A with other 
populations worldwide 
 
The modern human species - Homo 
sapiens sapiens - originated in sub-
Saharan Africa ~ 200,000 years ago, this 
species began migrating from Africa ~ 
70,000 years ago; Humans spread east and 
west populating Asia and Europe and just 
~ 20,000 years ago populated America 
(41). Thousands of years of geographic 
isolation were accompanied by a 
population genetic diversification, giving 
rise to the diverse human population 
groups that can be seen throughout the 
world to this day. The colonization of 
America and the slave trade brought the 
different populations into close and 
sustained contact and as a consequence, 
new mixed populations were created (42, 
43). This is particularly true for Latin 
America, where populations are 
characterized by high levels of genetic 
mixing between populations of African, 
European, and Native American origin 
(42, 44). 
 
The TYK2 P1104A variant is believed to 
have a European origin, having a current 
frequency of approximately 4.2%, the 
lowest frequency of P1104A is recorded in 
populations of non-European descent, 
including in particular its very low 
frequency in East Asia and Sub-Saharan 
Africa (37). Taking into account the 
above, specifically the Colombian 
population has an ancestral European 
component, but also African and 
indigenous; This study has been focused 
mainly on the studied sample of the 
population of Medellin, therefore it would 
not represent the ethnic complexity of the 
Colombian population. According to the 
study conducted by King Jordan (45) of 
Genetic Ancestry in Latin America, 
"Several genes regulated by ancestry-
specific SNPs were found to play specific 
roles in the immune system and in 
responses to infectious diseases. In 
particular, it was discovered that the genes 
of the immune system innate and adaptive 
are regulated by SNPs enriched by 
ancestry that exert specific regulatory 
effects on the population ". Furthermore, it 
was identified that the population of 
Medellín has a mostly European genetic 
ancestry, which would explain that we 
have patients with the P1104A 
polymorphism in a heterozygous state; 
This ancestral genetics varies at the level 
Guzmán LC, Arias AA, Barrera LF. 
 
 13 
of all Latin American populations, 
therefore, it cannot be certain or confirmed 
until more studies are carried out, how this 
variant is distributed at the level of the 





It is already certain that a large number of 
tuberculosis cases are related to P1104A in 
a homozygous state in European 
individuals, specifically in Latin American 
or Colombian individuals, no study has 
been carried out based on susceptibility to 
tuberculosis by this same variant. In this 
study, we did not find the variant in a 
homozygous state; however, we found the 
TYK2 P1104A variant in 19 Colombian 
patients in a heterozygous state, which is 
why it was assumed that other genetic 
variants within the same gene could create 
a predisposition to the development of TB 
active in these Colombian patients. This 
hypothesis was confirmed by sequencing 
and the p.Ala53Thr variant was found in 
two of the patients. This variant has not 
been reported in studies related to 
tuberculosis; however, studies are 
necessary to experimentally determine the 
phenotypic effect of this variant and define 
a potential effect on susceptibility to 
tuberculosis. However, we cannot rule out 
the possibility that a possible lack of 
sufficient statistical power may be limiting 
our results. In the future, the ideal would 
be to carry out a study at the Latin 
American level with Colombian, Chilean, 
Argentine and Brazilian populations, since 
they all have genetic components of 
ancestry. European, African and 
Indigenous in different proportions. This 
study is of great importance for public 
health and opens a great path for diverse 
investigations of clinical and genetic 
understanding for the management of 





Special thanks to the Primary 
Immunodeficiencies Group (IDP) and the 
Cellular and Immunogenetic Immunology 
Group (GICIG) of the University of 
Antioquia and especially to Dr Andres 
Augusto Arias and Dr Luis Fernando 
Barrera for facilitating the time, equipment 
and space for me learning. In the same 
way, to Julian Rojas and Carlos Arango 
and other people in the laboratory for their 
constant support. Finally, to the entire 
Guzmán LC, Arias AA, Barrera LF. 
 
 14 
faculty and to the EAFIT University, for 
providing me with the knowledge and 




1.  World Health Organization, GLOBAL TUBERCULOSIS REPORT 2019 (2020). 
2.  J. Furin, H. Cox, M. Pai, Tuberculosis. Lancet 393, 1642–1656 (2019). 
3.  S. Boisson-Dupuis, et al., Tuberculosis and impaired IL-23–dependent IFN- immunity 
in humans homozygous for a common TYK2 missense variant. Sci. Immunol. 3 
(2018). 
4.  R. Martínez-barricarte, et al., Human IFN-  immunity to mycobacteria is governed 
by both IL-12 and IL-23. 1–13. 
5.  Instituto Nacional de Salud, Protocolo de Vigilancia en Salud Pública-Tuberculosis: 
código 813. Inst. Nac. Salud, 1–36 (2017). 
6.  M. P. López Pérez, Informe Del Evento Tuberculosis, Colombia , 2014. 20 (2014). 
7.  Ministerio de Salud y Protección Social, Indicadores Básicos 2015 (2015). 
8.  OPS/OMS Organización Panamericana de la Salud/Organización Mundial de la Salud, 
Situación de la Tuberculosis en el Departamento de Antioquia 2015-2016. bia Boletín 
Inf. para la acción (2017). 
9.  S. J. El Baghdadi , A.V. Grant , A. Sabri , S. El Azbaoui , H. Zaidi , A. Cobat , E. 
Schurr, J. L. C. Boisson-Dupuis,  and L. Abel, Génétique humaine de la tuberculose. 
Magnesium 61, 1–2 (2010). 
10.  M. Pai, et al., Tuberculosis. Nat. Rev. Dis. Prim. 2 (2016). 
11.  R. M. G. J. Houben, P. J. Dodd, The Global Burden of Latent Tuberculosis Infection: 
A Re-estimation Using Mathematical Modelling. PLoS Med. 13, 1–13 (2016). 
12.  M. W. Borgdorff, et al., The incubation period distribution of tuberculosis estimated 
with a molecular epidemiological approach. Int. J. Epidemiol. 40, 964–970 (2011). 
13.  H. Esmail, C. E. Barry, D. B. Young, R. J. Wilkinson, The ongoing challenge of latent 
tuberculosis. Philos. Trans. R. Soc. B Biol. Sci. 369 (2014). 
14.  G. Churchyard, et al., What We Know about Tuberculosis Transmission: An 
Guzmán LC, Arias AA, Barrera LF. 
 
 15 
Overview. J. Infect. Dis. 216, S629–S635 (2017). 
15.  A. Cobat, M. Orlova, L. F. Barrera, E. Schurr, Host genomics and control of 
tuberculosis infection. Public Health Genomics 16, 44–49 (2013). 
16.  M. Möller, et al., Genetic Resistance to Mycobacterium tuberculosis Infection and 
Disease. Front. Immunol. 9, 2219 (2018). 
17.  W. X. Feng, et al., Tag SNP polymorphism of CCL2 and its role in clinical 
tuberculosis in Han Chinese pediatric population. PLoS One 6 (2011). 
18.  X. W. Li, et al., SLC11A1 (NRAMP1) polymorphisms and tuberculosis susceptibility: 
Updated systematic review and meta-analysis. PLoS One 6, 2–9 (2011). 
19.  X. Ma, et al., Association between interleukin-8 gene alleles and human susceptibility 
to tuberculosis disease. J. Infect. Dis. 188, 349–355 (2003). 
20.  X. Ma, et al., Full-exon resequencing reveals toll-like receptor variants contribute to 
human susceptibility to tuberculosis disease. PLoS One 2, 1–9 (2007). 
21.  C. M. Austin, X. Ma, E. A. Graviss, Common nonsynonymous polymorphisms in the 
NOD2 gene are associated with resistance or susceptibility to tuberculosis disease in 
African Americans. J. Infect. Dis. 197, 1713–1716 (2008). 
22.  K. Y. King, et al., Polymorphic allele of human IRGM1 is associated with 
susceptibility to tuberculosis in African Americans. PLoS One 6, 4–6 (2011). 
23.  J. Bustamante, S. Boisson-Dupuis, L. Abel, J. L. Casanova, Mendelian susceptibility 
to mycobacterial disease: Genetic, immunological, and clinical features of inborn 
errors of IFN-γ immunity. Semin. Immunol. 26, 454–470 (2014). 
24.  Bustamente et al, Cybb. 12, 213–221 (2011). 
25.  P. Tabarsi, et al., Lethal tuberculosis in a previously healthy adult with IL-12 receptor 
deficiency. J. Clin. Immunol. 31, 537–539 (2011). 
26.  A. A. Arias, et al., Severe Enteropathy and Hypogammaglobulinemia Complicating 
Refractory Mycobacterium tuberculosis Complex Disseminated Disease in a Child 
with IL-12Rβ1 Deficiency. J. Clin. Immunol. 37, 732–738 (2017). 
27.  A. Alcaïs, C. Fieschi, L. Abel, J. L. Casanova, Tuberculosis in children and adults: 
Two distinct genetic diseases. J. Exp. Med. 202, 1617–1621 (2005). 
28.  J. Bustamante, et al., BCG-osis and tuberculosis in a child with chronic granulomatous 
disease. J. Allergy Clin. Immunol. 120, 32–38 (2007). 
Guzmán LC, Arias AA, Barrera LF. 
 
 16 
29.  J. Bustamante, Mendelian susceptibility to mycobacterial disease: recent discoveries. 
Hum. Genet. 139, 993–1000 (2020). 
30.  P. Shah, M. El-Maaytah, W. Jerjes, T. Upile, P. Ayliffe, Interleukin 12 Receptor β1 
Chain Deficiency in a Child With Disseminated Tuberculosis: A Case Report. J. Oral 
Maxillofac. Surg. 68, 909–911 (2010). 
31.  I. Caragol, et al., Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor 
β1 deficiency. Clin. Infect. Dis. 37, 302–306 (2003). 
32.  A. Y. Kreins, et al., Human TYK2 deficiency: Mycobacterial and viral infections 
without hyper-IgE syndrome. J. Exp. Med. 212, 1641–1662 (2015). 
33.  C. Fieschi, et al., Low penetrance, broad resistance, and favorable outcome of 
interleukin 12 receptor β1 deficiency: Medical and immunological implications. J. 
Exp. Med. 197, 527–535 (2003). 
34.  C. J. A. Duncan, et al., Human IFNAR2 deficiency: lessons for antiviral immunity 
Europe PMC Funders Group. Sci Transl Med 7, 307–154 (2015). 
35.  H. Mao, et al., Exome sequencing identifies novel compound heterozygous mutations 
of IL-10 receptor 1 in neonatal-onset Crohn’s disease. Genes Immun. 13, 437–442 
(2012). 
36.  K. R. Engelhardt, B. Grimbacher, IL-10 in humans: Lessons from the Gut, IL-10/IL-
10 receptor deficiencies, and IL-10 polymorphisms. Curr. Top. Microbiol. Immunol. 
380, 1–18 (2014). 
37.  G. Kerner, et al., Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% 
of patients in a cohort of European ancestry. Proc. Natl. Acad. Sci. U. S. A. 116, 
10430–10434 (2019). 
38.  H. del Corral, et al., IFNc response to Mycobacterium tuberculosis, risk of infection 
and disease in household contacts of tuberculosis patients in Colombia. PLoS One 4 
(2009). 
39.  C. Mauricio Rojas, et al., Características clínicas, epidemiológicas y microbiológicas 
de una cohorte de pacientes con tuberculosis pulmonar en Cali, Colombia. Biomédica 
30, 482–491 (2010). 
40.  D. A. Dyment, et al., <Znl406.Pdf> (2012). 
41.  K. R. Veeramah, M. F. Hammer, The impact of whole-genome sequencing on the 
Guzmán LC, Arias AA, Barrera LF. 
 
 17 
reconstruction of human population history. Nat. Rev. Genet. 15, 149–162 (2014). 
42.  A. Ruiz-Linares, et al., Admixture in Latin America: Geographic Structure, 
Phenotypic Diversity and Self-Perception of Ancestry Based on 7,342 Individuals. 
PLoS Genet. 10 (2014). 
43.  S. Wang, et al., Geographic patterns of genome admixture in latin American mestizos. 
PLoS Genet. 4, 1–9 (2008). 
44.  J. R. Homburger, et al., Genomic Insights into the Ancestry and Demographic History 
of South America. PLoS Genet. 11, 1–26 (2015). 
45.  E. T. Norris, et al., Genetic ancestry, admixture and health determinants in Latin 



























Table 1: Oligonucleotides used for TYK2 PCR and sequencing. 
 
Exon Oligonucleotides name Oligonucleotides sequence (5´-3´) 
ex3 TYK2-1F AGATGGGAGCCCAGAATCTT 
 TYK2-1R CAGCTGCTGCTTGCACAC 
ex4-5 TYK2-2F GTCTTTGGGGCTGACGGTAG 
 TYK2-3R AAATGGGGGCTCCTCAACT 
ex6 TYK2-4F TGTAGGGCCCAAGACACTTC 
 TYK2-4R GTCTACCCTGGCTCCCAGAT 
ex7 TYK2-5F ACCTGGCTAGTGTGCCTGTT 
 TYK2-5R TCAGAGGCTAGGGGTCAAGGA 
ex8-9 TYK2-6F GGGGAAAGTGCAGGAGGTAT 
 TYK2-7R CCCCTAGGGCTCACAGTCTA 
ex10-12 TYK2-8F GCTGTGTGTGTGCCCTCTAA 
 TYK2-10R GAATACCGCCATGGTGAAAG 
ex13-14 TYK2-11F CGGGTTGACCAGAAGGAGAT 
 TYK2-12R GAGGGTTGGGGTACAGATCA 
ex15 TYK2-13F CTGCATTCCGCATTTCTTCT 
 TYK2-13R AGGGCGAAACTCCACCTAAA 
ex16-17 TYK2-14F TCACATTGGCTGTCCCTATG 
 TYK2-15R AGAAGGGATGCAGCTTTGAG 
ex18 TYK2-16F CTCTGGGGACTTGACTCTGC 
 TYK2-16R GCTTATGAATGCCACTGCAA 
ex19-20 TYK2-17F AGAATCGGATCCTGGGGTAG 
 TYK2-18R CTCACCCAGATGCCAAGAAC 
ex21 TYK2-19F CTCTGCTGGGCTCAAGGTAG 
 TYK2-19R AACAGTTCGGAGGTCAGTGC 
ex22 TYK2-20F CTTTCTGGCTCAGCCTCCTT 
 TYK2-20R GGGTGATATGCTCATTGGCTA 
ex23 TYK2-21F AAGGGGCGGTGTATAGAGTG 
 TYK2-21R TCTCGATCTCCTGACCTCGT 
ex24-25 TYK2-22F TGGGATTACAGGCATGAGC 
 TYK2-23R ATCCCCCTCTTGGTTTCATC 
 
 
Table 2: Description of the standardization for the PCR master mix 






Table 3: Description of the individual conditions for each of the amplified exons 
 
EXON ANNELING TEMPERATURE 𝑀𝑔𝐶𝑙2 CONCENTRATION 
3 61,8°C 2,5 mM 
4 and 5 61,8°C 1,5 mM 
6 60,1°C 2 mM 
7 62,3°C 2,5 mM 
8 and 9 61,8°C 2,5 mM 
10, 11 and 12 58°C 2,5 mM 
13 and 14 61,8°C 2,5 mM 
15 60,3°C 2,5 mM 
16 and 17 52,5°C 2,5 mM 
18 61,2°C 2 mM 
19 and 20 55°C 2 mM 
21 69,8°C 2 mM 
22 64°C 2 mM 
23L 67,9°C 1,5 mM 
23S 56,7°C 2,5 mM 
 
 
Table 4: Example of the machine and samples for qPCR 
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Figure 1: Description of the thermocycler conditions 
 
 
 
 
